Get the Stockscreener App
143.75
0.45%
0.64
Novartis Ag Adr stock is traded at $143.75, with a volume of 1.90M.
It is up +0.45% in the last 24 hours and up +4.56% over the past month.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
See More
Previous Close:
$143.11
Open:
$142.92
24h Volume:
1.90M
Relative Volume:
1.00
Market Cap:
$273.23B
Revenue:
$54.66B
Net Income/Loss:
$13.58B
P/E Ratio:
20.49
EPS:
7.0171
Net Cash Flow:
$16.05B
1W Performance:
+1.95%
1M Performance:
+4.56%
6M Performance:
-7.29%
1Y Performance:
+9.68%
1-Day Range:
$142.80
$143.96
1-Week Range:
$139.31
$144.28
52-Week Range:
$121.57
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Name
Novartis Ag Adr
Sector
Industry
Phone
-
Address
-
Compare NVS vs LLY, JNJ, ABBV, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
143.75 | 273.23B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,179.27 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.44 | 630.04B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
276.47 | 488.55B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.60 | 359.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-26 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-09-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-09-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-11-26 | Upgrade | Argus | Hold → Buy |
| Jan-27-26 | Initiated | Citigroup | Buy |
| Jan-06-26 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-12-25 | Downgrade | Goldman | Neutral → Sell |
| Aug-08-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-13-25 | Downgrade | UBS | Buy → Neutral |
| Feb-12-25 | Initiated | Morgan Stanley | Underweight |
| Feb-04-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Dec-04-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Sep-11-24 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-05-24 | Downgrade | Goldman | Buy → Neutral |
| Sep-03-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-24 | Downgrade | Deutsche Bank | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-23-24 | Initiated | BMO Capital Markets | Market Perform |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-25-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-26-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-27-23 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-26-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-05-22 | Upgrade | Stifel | Hold → Buy |
| Sep-15-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| May-09-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-10-22 | Resumed | Citigroup | Buy |
| Dec-14-21 | Downgrade | Redburn | Buy → Neutral |
| Dec-06-21 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-03-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Sep-20-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-22-21 | Initiated | Bernstein | Mkt Perform |
| Mar-10-21 | Downgrade | Argus | Buy → Hold |
| Feb-01-21 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Sep-10-20 | Upgrade | UBS | Neutral → Buy |
| Sep-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-15-20 | Upgrade | Citigroup | Neutral → Buy |
| Mar-10-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-25-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-10-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-02-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Underperform → Buy |
| May-29-18 | Downgrade | HSBC Securities | Buy → Hold |
| May-25-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jan-25-18 | Reiterated | Leerink Partners | Outperform |
| Dec-06-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-17 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jul-05-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Mar-09-17 | Initiated | Liberum | Buy |
View All
Novartis Ag Adr Stock (NVS) Latest News
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - The Globe and Mail
Swiss Market Index Retreats; Novartis Shares Decline - marketscreener.com
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - Zacks Investment Research
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AGNVS - PR Newswire
Novartis wins FDA approval for a form of chronic hives - marketscreener.com
AI companies run virtual drug trials, aim to improve success of human studies - Reuters
Novartis AG (CEUX:1NOVNM) Cyclically Adjusted Price-to-FCF : (As of Oct. 07, 2026) - GuruFocus
US FDA expands use of Novartis drug for chronic skin condition - Reuters
Why Is Novartis Stock Trading Higher Today?Novartis (NYSE:NVS) - Benzinga
Novartis (NVS) Secures FDA Approval for Rhapsido, Expanding Trea - GuruFocus
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU) - The Manila Times
Novartis Rhapsido® (remibrutinib) receives FDA approval as - GlobeNewswire
Novartis to Present Key Data on Multiple Sclerosis - marketscreener.com
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026 - marketscreener.com
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026 - GlobeNewswire Inc.
Novartis advances multiple sclerosis innovation with - GlobeNewswire
The patient who changed the course of my career - Novartis
Novartis AG (SWX: NOVN): Now September Has Ended, Is It Now Time To Buy? - Stocks Down Under
Novartis Sues Apotex Over Mekinist Copies, Tafinlar Drug Combo - Bloomberg Law News
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal - Zacks Investment Research
Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026 - GlobeNewswire Inc.
BofA Expects Higher Q3 Sales From Novartis Amid Strong Key Growth Drivers - Moomoo
Should You Invest in the VanEck Pharmaceutical ETF (PPH)? - Zacks Investment Research
Total non-current liabilities of Novartis AG – BX:NOT - TradingView
NOVARTIS AG N (NOTA.F) Q2 FY2026 earnings call transcript - Yahoo Finance
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion - Zacks Investment Research
Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity - GlobeNewswire Inc.
Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion - Bloomberg.com
Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights - GlobeNewswire Inc.
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Novartis faces securities fraud probe after dru... - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AGNVS - prnewswire.com
Novartis AG : Receives a Sell rating from Goldman Sachs - marketscreener.com
Novartis Falls as Investors Continue to Digest September Trial Setbacks - Quiver Quantitative
Novartis AG (CEUX:1NOVNm) Stock Price & 30 Year Financial Data - GuruFocus
Community health takes a village: from Pulpit to Pew - Novartis
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities - GlobeNewswire Inc.
Gross margin % of Novartis AG Sponsored ADR – HAN:NOTA - TradingView
Net margin % of Novartis AG Sponsored ADR – HAN:NOTA - TradingView
Novartis AG (NVS) Shares Fall 0.8% -- What GF Score of 78 Tells Investors - GuruFocus
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis AG : Deutsche Bank reiterates its Neutral rating - marketscreener.com
Novartis (NVS) Has More Growth Ahead. Can its Portfolio Outrun Generic Pressure? - Yahoo Finance
Novartis AG Stock Warning Signs - GuruFocus
Novartis AG Hired Firms, 2003 - OpenSecrets
Novartis AG Lobbyists, 1998 - OpenSecrets
Novartis AG Agencies, 2026 - OpenSecrets
Novartis AG Lobbyists, 2026 - OpenSecrets
Novartis (NYSE:NVS) Offers Dividend Investors a Quality Income Profile - ChartMill
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover? - Yahoo Finance
Novartis Ag Adr Stock (NVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novartis Ag Adr Stock (NVS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Marshall Fiona | Officer |
Feb 12 '26 |
Proposed Sale |
161.35 |
30,743 |
4,960,277 |
0 |
| Bulto Carulla Victor | Officer |
Feb 09 '26 |
Proposed Sale |
156.21 |
7,500 |
1,171,576 |
0 |
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):